| Name | Title | Contact Details |
|---|---|---|
Simon Sweet |
Director Of Information Technology | Profile |
MANUFACTURING Philosophy The TRC team understands that the actions required to be a successful pharmaceutical manufacturer are more than just completing repetitive and highly detailed tasks accurately; it is the understanding that we...
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.
Cardinal Health, Inc. is an American multinational health care services company, and the 14th highest revenue generating company in the United States.
Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.
Bryn Pharma is a privately held pharmaceutical company based in North Carolina. Primary focus is on the development and commercialization of innovative allergy products for the management of anaphylaxis.